Mark Humbert, M.D., Ph.D.
Marc Humbert, MD, PhD, is Professor of Respiratory Medicine at the South Paris University (Université Paris-Saclay) in Le Kremlin-Bicêtre, France since 1999. In addition to his academic responsibilities, he is the Director of the National Reference Centre for Pulmonary Hypertension, Department of Respiratory and Intensive Care Medicine, Hospital Bicêtre, Assistance Publique Hôpitaux de Paris, France. Along with membership to several scientific councils and institutes, Marc Humbert is the current Director of the INSERM Unit “Pulmonary Hypertension: Pathophysiology and Innovative Therapies” and of the “Thorax Innovation” University Hospital Department. He has been the Chief Editor of the European Respiratory Journal from 2013 to 2017. He has published more than 700 peer-reviewed articles, mostly in the field of pulmonary hypertension. He is a Fellow of the European Respiratory Society (FERS Foundation Fellow) and has received several distinctions including the 1997 François Brenot Award and the 2006 Cournand Lecture Award from the ERS, the 2009 Descartes-Huygens Award from the Royal Netherlands Academy of Arts and Sciences, the 2016 Rare Disease Award of the Fondation de France and the 2018 ERS Award for Lifetime Achievement in Pulmonary Arterial Hypertension. Since 2017, Marc Humbert is the vice-coordinator of the European Reference Network for rare and low prevalence respiratory diseases (ERN-LUNG). Clarivate Analytics listed Marc Humbert as one of the world’s highly cited researchers in the field of Clinical Medicine (2018).
Dr. R James White III, M.D., Ph.D.
Dr. Jim White has spent twenty years at the University of Rochester Medical Center (URMC) and is the founding director of the University’s pulmonary arterial hypertension (PAH) program. He has been the principal investigator for Phase 2 and 3 programs conducted there and is now sharing that responsibility with his partner, Dan Lachant. URMC is the region’s leading referral center for patients with pulmonary vascular diseases and has received accreditation as a Comprehensive Care Center from the Pulmonary Hypertension Association in recognition of excellence in diagnosis, research and clinical care.
In his bench laboratory, Dr. White’s research focuses on understanding the vascular biology of PAH and serving as a test ground to compare late stage preclinical compounds to currently available treatments. He has participated in clinical trials for numerous experimental PAH medications, including tadalafil, ambrisentan, riociguat, bardoxolone, and rituxan (in scleroderma-associated PAH.) He is the academic leader for the development of oral treprostinil.
In addition to his clinical and academic responsibilities, Dr. White provides scientific and development advice to biopharmaceutical companies including PhaseBio, United Therapeutics, Reata Pharmaceuticals, Gilead, Bayer and Celtaxsys. He has published over 30 clinical articles and was awarded a patent in 2005 for the use of tissue factor pathway inhibitors and protease activated receptor 1 antagonists for the treatment of PAH.
Dr. White earned his M.D. and Ph.D. degrees while in an NIH-funded Medical Scientist Training Program at the University of Pittsburgh under the mentorship of Dr. Ian Reynolds. Thereafter, he completed residency training in internal medicine and a fellowship in pulmonary and critical care at the University of Rochester.